Therefore, the ability to transcriptionallytarget both of these aberrant phenotypes and induce cell death incolon cancer cells through the use of single class I HDAC inhibitorsand novel degraders, such as PROTACs described here, offers an excitingpotential avenue for the clinical treatment of colon cancer. Here, HDAC9 is linked to malignant colon neoplasm.